When Israeli 3D printing company Nano Dimension gets coverage in the news, the discussion generally revolves around the intensive and long-awaited development of their electronic 3D printing system, the DragonFly2020. Since unveiling their desktop electronic 3D printer towards the end of last year, the company has had a momentous start to 2016. Aside from preparing for the manufacturing and distribution of the DragonFly2020, Nano Dimension has been working to develop a 3D printable nickel nano ink in collaboration with Tel Aviv University, and has also listed the company to begin trading on the NASDAQ.
With all of the developments taking place with their electronic 3D printing technology, it’s hard to imagine that the Nano Dimension team currently has any time to pursue other pivotal 3D printing projects. Well, it looks as if the electronics 3D printing company will indeed be venturing into other research areas, this time with 3D bioprinting. Collaborating with the premier stem cell culturing solutions provider Accellta Ltd., which is based in Haifa, Israel, Nano Dimension has just announced that they’ve successfully lab-tested a proof of concept 3D bioprinter for producing stem cell-derived tissues.
“Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies,” noted Accellta’s Chairman and CEO, Dr. Itzchak Angel. ” We hope and believe that this will bring the mutual capabilities and know-how of both companies to create 3D bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision 3D bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development. We are very excited about these initial results and what the future holds.”
The collaborative feasibility study, which was conducted over the second quarter of 2016, shows that their combined knowledge and technology has enabled the two companies to 3D print viable stem cells with a modified 3D printer. Utilizing Nano Dimension’s highly precise inkjet 3D printing capabilities, along with Accellta’s 15 years of experience in developing stem cell suspension technologies, their study thus far has proved to be a successful one. Working together, the two companies have showcased their potential to accelerate high fidelity and high viability production of living cellular products.
“3D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control and viability as well as cell availability and bio-ink technologies,” said Amit Dror, CEO of Nano Dimension. “By combining our high speed, high precision inkjet capabilities with Accellta’s stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable 3D printing at high resolution and high volumes.”
According to IDTechEx, the value of the 3D bioprinting market is projected to reach $6 billion by 2024, and is expected to improve a number of medically-driven areas, including pre-clinical drug discovery and testing, cosmetics safety testing, toxicology assays, and of course, tissue printing. By utilizing high precision 3D bioprinting and differentiation of stem cells into required tissues, Nano Dimension and Accellta are on the brink of enabling even greater capabilities for 3D bioprinting. The joint research may soon turn into a joint venture too, as both companies are considering the formation of an entirely new entity together in order to continue investigating future bioprinting solutions and raise funding for the continuation of their research.
Although Nano Dimension may seem fixated on electronics 3D printing technology at times, their true aim seems to be advancing their 3D inkjet technology in a multitude of ways. It’s clear that their recent developments in 3D printed electronics and circuit boards have helped set the stage for their collaborative multi-material bioprinting research, which could soon help thrust them forth into the high-demand medical market, much like they’re already set to do within the electronics industry in the near future. What do you think of this latest industry partnership? Discuss further in the Nano Dimension & Accellta Teaming up to Further 3D Printing forum over at 3DPB.com.
You May Also Like
New Data Report: 3D Printing Revenues Reached $2.12B in Q3 2020, Says SmarTech Analysis
Due to the COVID-19 pandemic, the global economy took a steep nose dive in 2020. This included the 3D printing market during the first half of the year, but our...
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest from...
3D Printing Webinar and Virtual Event Roundup: January 17, 2021
We’ve got all kinds of virtual events and webinars to share with you this week, with topics ranging from 3D design and medical applications to simulation and more. Read on...
Desktop Metal (DM) Buys EnvisionTEC to Quickly Boost Revenues?
Wow. Publicly traded Desktop Metal (NYSE:DM) has just purchased EnvisionTEC for $300 million in stock and cash. For my part, I would have paid all my money to be a...
View our broad assortment of in house and third party products.